Home        Sitemap        Contact us 
Publications
 
 
Patents
Of 6 Patents in the portfolio of Arrien Pharmaceuticals Drug Discovery efforts includes issued, published and pending patent application being filed with both USPTO and PCT.
  1. Feb. 16, 2016
    U.S. Patent and Trademark Office issued U.S. Patents No. 9,260,426 B2; Feb. 16, 2016.
    The term of the patent is 20 years from the earliest effective filing data Dec. 9, 2013, pharmaceutical composition of matter claims comprising of pre-clinical stage ARN-3261 and related compounds useful as protein kinase inhibitor, specifically SIK2 (Salt Inducible Kinase-2) for the treatment of cancer, stroke, cardiovascular, obesity and type II diabetes. PCT National Stage entry filed.
  2. Dec. 08, 2015
    U.S. Patent and Trademark Office issued U.S. Patents No. 9,206,188 B2; Dec. 08, 2015.
    The term of the patent is 20 years from the earliest effective filing data April 16, 2014, pharmaceutical composition of matter claims comprising of pre-clinical stage ARN-4079 and related compounds useful as protein kinase inhibitor, specifically JAK3 for the treatment of autoimmune, inflammation, rheumatoid arthritis, and psoriasis diseases. PCT National Stage entry filed.
  3. Nov. 17, 2015
    U.S. Patent and Trademark Office issued U.S. Patents No. 9,187,473 B2; Nov. 17, 2015.
    The term of the patent is 20 years from the earliest effective filing data May 2014, pharmaceutical composition of matter claims comprising of pre-clinical stage ARN-1104 and related compounds useful as protein kinase inhibitors, specifically LRRK2 (Leucine-Rich Repeat Kinase-2) for the treatment of Parkinson's Disease, Alzheimer's Disease, Down's Syndrome, Huntington's Disease, other Neurodegenerative and Central Nervous System disorders.
  4. March 18, 2015
    U.S. Patent and Trademark Office issued U.S. Patents No. 8,791,112 B2; July 29, 2014.
    The term of the patent is 20 years from the earliest effective filing data March 2013, pharmaceutical composition of matter claims comprising of pre-clinical stage ARN-1104 and related compounds useful as protein kinase inhibitors, specifically LRRK2 (Leucine-Rich Repeat Kinase-2) for the treatment of Parkinson's Disease, Alzheimer's Disease, Down's Syndrome, Huntington's Disease, other Neurodegenerative and Central Nervous System disorders.
 
Copyright © 2011, Arrien Pharmaceuticals, LLC. All rights reserved.